This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muntner, P. Articles by Whelton, P. K. Search for Related Content PubMed PubMed Citation Articles by Muntner, P. Articles by Whelton, P. K. Related Collections Other hypertension Other Treatment Arrhythmias, clinical electrophysiology, drugs

(Hypertension. 2002;39:897.)
© 2002 American Heart Association, Inc.

Scientific Contributions

The Impact of JNC-VI Guidelines on Treatment Recommendations in the US Population

Paul Muntner; Jiang He; Edward J. Roccella; Paul K. Whelton

From the Department of Epidemiology (P.M., J.H., P.K.W.), Tulane University School of Public Health and Tropical Medicine, and Department of Medicine (J.H., P.K.W.) Tulane University School of Medicine, New Orleans, La; and National Heart, Lung and Blood Institute (E.J.R.), Bethesda, Md.

Correspondence to Paul Muntner, Department of Epidemiology, Tulane University SPHTM, 1430 Tulane Ave, SL-18, New Orleans, LA 70112. E-mail pmuntner{at}tulane.edu

Using epidemiological and clinical trial evidence, the sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC-VI) updated previous guidelines to suggest that in addition to blood pressure, decisions on initial treatment should emphasize absolute cardiovascular disease risk. We estimated the impact of using cardiovascular disease risk on treatment recommendations for the US population using data from 16 527 participants in the Third National Health and Nutrition Examination Survey. In the US population 20 years of age, 36% (62 million) had high-normal blood pressure or greater (systolic/diastolic blood pressure 130 mm Hg/85 mm Hg) or were taking antihypertensive medication. Of this population, 5.1% (3.2 million) were stratified into risk group A (no cardiovascular disease risk factors or prevalent cardiovascular disease), 66.3% (41.4 million) into risk group B (1 major risk factor), and 28.6% (17.9 million) into risk group C (diabetes mellitus, clinical cardiovascular disease, target organ damage). Also, 26% of this group (16.2 million) had high-normal blood pressure and were in risk groups A or B, a context in which vigorous lifestyle modification is recommended in the JNC-VI guidelines. Additionally, 11% (7.0 million) had high-normal blood pressure (systolic/diastolic, 130 to 139 mm Hg/85 to 89 mm Hg, respectively) or stage-1 hypertension (140 to 159 mm Hg/90 to 99 mm Hg), and at least 1 factor, placing them in risk group C, but they were not currently on antihypertensive medication. JNC-VI, but not previous JNC guidelines, specifically recommends drug therapy as initial treatment for these patients. We conclude that JNC-VI refines cardiovascular risk and enfranchises more Americans to undertake more aggressive risk reduction maneuvers.

Key Words: guidelines • treatment • drug therapy • lifestyle

This article has been cited by other articles:

				L. Tolkin, M. Bursztyn, I. Z. Ben-Dov, N. Simanovsky, and N. Hiller Incidental renal artery calcifications: a study of 350 consecutive abdominal computed tomography scans Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2170 - 2175. [Abstract] [Full Text] [PDF]

				H. Cakir and R. Pinar Randomized Controlled Trial on Lifestyle Modification in Hypertensive Patients West J Nurs Res, March 1, 2006; 28(2): 190 - 209. [Abstract] [PDF]

				J. Arnlov, M. J. Pencina, B.-H. Nam, J. B. Meigs, C. S. Fox, D. Levy, R. B. D'Agostino, and R. S. Vasan Relations of Insulin Sensitivity to Longitudinal Blood Pressure Tracking: Variations With Baseline Age, Body Mass Index, and Blood Pressure Circulation, September 20, 2005; 112(12): 1719 - 1727. [Abstract] [Full Text] [PDF]

				J. R. Banegas, J. Segura, L. M. Ruilope, M. Luque, R. Garcia-Robles, C. Campo, F. Rodriguez-Artalejo, J. Tamargo, and on behalf of the CLUE Study Group Investigators Blood Pressure Control and Physician Management of Hypertension in Hospital Hypertension Units in Spain Hypertension, June 1, 2004; 43(6): 1338 - 1344. [Abstract] [Full Text] [PDF]

				D. W. Jones and J. E. Hall Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Evidence From New Hypertension Trials Hypertension, January 1, 2004; 43(1): 1 - 3. [Full Text] [PDF]

				Writing Group of the PREMIER Collaborative Researc Effects of Comprehensive Lifestyle Modification on Blood Pressure Control: Main Results of the PREMIER Clinical Trial JAMA, April 23, 2003; 289(16): 2083 - 2093. [Abstract] [Full Text] [PDF]